Kenvue Inc.

Kenvue Inc. (KVUE) priced its initial public offering on May 4, 2023 at $22.00 per share, raising $3.8B, and listed on NYSE. At the IPO price its market capitalization was about $41.56B. Goldman Sachs was lead-left underwriter, joined by J.P. Morgan, BofA Securities and Citigroup and others. Cravath advised the company and Davis Polk advised the underwriters.

Kenvue Inc. is a consumer health company with $15.0 billion in net sales in 2022. Its portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson's, Band-Aid, Aveeno, Zyrtec and Nicorette, which reach about 1.2 billion people.

Status

IPO

Ticker

KVUE

Exchange

NYSE

Priced

May 4, 2023

IPO price

$22.00

Raised

$3.8B

Market cap at IPO price

$41.56B

First filed

Jan 4, 2023

Underwriters

Goldman Sachs, J.P. Morgan, BofA Securities, Citigroup, Deutsche Bank, HSBC, RBC Capital Markets, UBS, ING, Santander, Academy Securities and Ramirez & Co.

Company counsel

Cravath

Underwriters' counsel

Davis Polk

Sector

Industrials & materials

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.